The report details the company's progress in accelerating life-saving therapies, leading with integrity, inspiring their people, and protecting the planet. The report includes detailed data and metrics for each ESG pillar. Some key highlights include that the company supported more than 80% of the drugs approved by the FDA in the last five years, made significant progress towards their 2030 climate change commitments, including the achievement of 92% renewable electricity usage globally, and continued to make progress in their DE&I programs. The report also highlights the company's commitment to animal welfare and its focus on continuous improvement in all areas of its operations.
Issuing Company Charles River Laboratories International Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 13.26 MB
No. of Pages 90 pages
Reporting period2022-2023
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB
Materiality Assessmenttrue